HIGHTIDE-B (02511.HK) will hold a Board of Directors meeting on March 28 to review and approve the annual performance.

Gelonghui reported on March 14 that HIGHTIDE-B (02511.HK) announced that the Board of Directors meeting will be held on March 28, 2025 (Friday) to review and approve the audited annual performance of the company and its subsidiaries for the year ended December 31, 2024, and its release, as well as to address Other matters.

Gelonghui FinanceMar 14 17:43

All the way up! The Innovative Drugs Sector in Hong Kong stocks surged collectively, with multiple stocks doubling this year. Who is reshaping the valuation?

The rise in the Hong Kong stock market's Innovative Drugs Sector continues. Market analysts point out that this wave of Innovative Drugs momentum benefits from a combination of factors including market sentiment, policy, and the realization of the companies' own commercial value.

Securities TimesMar 13 09:50

Significant adjustments to the Hang Seng series Index, what is the impact? Institutions: Alibaba and others may face passive Shareholding due to large increase.

This adjustment has a significant impact on leading stocks, with Alibaba, Tencent, HSBC, Xiaomi, and SMIC being passively reduced due to their large gains exceeding 8%, resulting in passive Outflow of funds. The adjustment officially took effect on March 10.

CITIC Securities Insight.Feb 24 10:16

What does AI pharmaceuticals still lack before a market explosion? | Focus

① From the discovery of targets to the identification of preclinical candidate compounds, current generative AI mainly focuses on the early stages of drug development, which can lead to significant acceleration; ② If AI in drug development is to further expand the realm of possibilities, it must explore more profitable real-world applications.

cls.cnJan 20 08:34

HighTide Therapeutics Enrolls Patients for Phase 3 Clinical Trial of Metabolic, Digestive Diseases Drug

MT NewswiresJan 2 15:19

HIGHTIDE-B (02511) has completed the patient enrollment for the HTD1801 head-to-head treatment of Dapagliflozin in a phase III clinical trial for type 2 diabetes.

HIGHTIDE-B (02511) announced that the company's independently developed intestinal and hepatic anti-inflammatory and metabolic regulator ursodeoxycholic acid...

Zhitong FinanceJan 2 12:06